Repair of Impaired Pulmonary Function Is Possible in Very-Long-Term Allogeneic Stem Cell Transplantation Survivors Natasha A. Jain, Priyanka A. Pophali,

Slides:

Advertisements

Similar presentations

Brandon Stone, MD, Victor S. Mangona, MD, Matthew D

Advertisements

Accelerated Bone Mineral Density Loss Occurs with Similar Incidence and Severity, But with Different Risk Factors, after Autologous versus Allogeneic.

Hypertension and Diabetes Mellitus in Adult and Pediatric Survivors of Allogeneic Hematopoietic Cell Transplantation Navneet S. Majhail, MD, MS, Tejo.

A Prospective Study of Iron Overload Management in Allogeneic Hematopoietic Cell Transplantation Survivors Navneet S. Majhail, Hillard M. Lazarus, Linda.

Vaccination of Children following Allogeneic Stem Cell Transplantation

Hematopoietic Cell Transplantation Provides Durable Disease Control in Patients with Double-Hit Lymphoma Taewoong Choi, Murali K. Kodali, Wen-Kai Weng

Increased Risk of Cervical Dysplasia in Long-Term Survivors of Allogeneic Stem Cell Transplantation—Implications for Screening and HPV Vaccination Bipin.

Brandon Stone, MD, Victor S. Mangona, MD, Matthew D

Jason M. Elinoff, Ulas Bagci, Brad Moriyama, Jennifer L

Continuous Intravenous Immunoglobulin and Platelet Infusion in Allogeneic Stem Cell Transplant Patients with Allo-Immune Thrombocytopenia Katerina Ancevski,

Allogeneic Stem Cell Transplantation in Myelofibrosis

Inhaled Cyclosporine Solution for the Treatment of Bronchiolitis Obliterans Following Hematopoietic Stem Cell Transplantation (HSCT) or Lung Transplantation

Outcome of Respiratory Syncytial Virus Lower Respiratory Tract Disease in Hematopoietic Cell Transplant Recipients Receiving Aerosolized Ribavirin: Significance.

Sabina Kersting, Leo F. Verdonck

Lung Function after Allogeneic Hematopoietic Stem Cell Transplantation in Children: A Longitudinal Study in a Population-Based Cohort Hilde Hylland Uhlving,

Vascular Endothelial Growth Factor and Activin-A Serum Levels Following Allogeneic Hematopoietic Stem Cell Transplantation David Nachbaur, Petra Schumacher,

Absolute Lymphocyte Count on Day 30 Is a Surrogate for Robust Hematopoietic Recovery and Strongly Predicts Outcome after T Cell-Depleted Allogeneic Stem.

Donor KIR Genes 2DL5A, 2DS1 and 3DS1 Are Associated with a Reduced Rate of Leukemia Relapse After HLA-Identical Sibling Stem Cell Transplantation for.

Betty T. Tran, Abigail Halperin, Jason W. Chien

Let Them Eat! Comparing a Neutropenic Diet to a Food Safety Based Diet in Patients Undergoing Hematopoietic Stem Cell Transplantation (HSCT) Cynthia.

Outcome and Prognostic Factors for Patients Who Relapse after Allogeneic Hematopoietic Stem Cell Transplantation Gita Thanarajasingam, Haesook T. Kim,

Jane Kempenich, Kelly Buck, John Hermanson, Jason Dehn, MPH

Decision Analysis of Peripheral Blood versus Bone Marrow Hematopoietic Stem Cells for Allogeneic Hematopoietic Cell Transplantation Joseph Pidala, Claudio.

Randomized Double-Blind Study of the Safety and Immunogenicity of Standard-Dose Trivalent Inactivated Influenza Vaccine versus High-Dose Trivalent Inactivated.

Increased Risk of Bone Loss without Fracture Risk in Long-Term Survivors after Allogeneic Stem Cell Transplantation Bipin N. Savani, Theresa Donohue,

Symptom Distress Predicts Long-Term Health and Well-Being in Allogeneic Stem Cell Transplantation Survivors Margaret F. Bevans, Sandra A. Mitchell, John.

Cytomegalovirus Infection after Allogeneic Transplantation: Comparison of Cord Blood with Peripheral Blood and Marrow Graft Sources Christopher M. Walker,

Christopher C. Dvorak, Rajni Agarwal, Gary V. Dahl, John J

Recovery of Pulmonary Function after Allogeneic Hematopoietic Cell Transplantation in Children Predicts Improved Survival Ashok Srinivasan, William Mitchell,

Evaluating the Impact of Antithymocyte Globulin on Lung Function at 1 Year after Allogeneic Stem Cell Transplantation Filippo Milano, Margaret A. Au,

Time to Insurance Approval in Private and Public Payers Does Not Influence Survival in Patients Who Undergo Hematopoietic Cell Transplantation Vijaya.

Total Marrow Lymphoid Irradiation/Fludarabine/ Melphalan Conditioning for Allogeneic Hematopoietic Cell Transplantation Lindsay G. Jensen, Tracey Stiller,

Improvement of Pulmonary Function with Imatinib Mesylate in Bronchiolitis Obliterans Following Allogeneic Hematopoietic Cell Transplantation Navneet.

Bone Mineral Density (BMD) Improves in Survivors in Their Second Decade Post- Allogeneic Stem Cell Transplantation and Is Influenced By Body Mass Index.

ST2 is Associated with GVHD in Ex Vivo Graft Manipulation Strategies for Allogeneic Peripheral Blood Stem Cell Transplantation Caroline R. Cantilena,

Favorable Outcomes in Patients Surviving 5 or More Years after Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies Robert.

HLA Haploidentical Stem Cell Transplant with Pretransplant Immunosuppression for Patients with Sickle Cell Disease Anna B. Pawlowska, Jerry C. Cheng,

Biology of Blood and Marrow Transplantation

Sandra Miklos, Gunnar Mueller, Yayi Chang, Thomas E. O

Relationship of CMV Reactivation and Rabbit Antithymocyte Globulin Administration in Allogeneic Stem Cell Transplant Patients LeAnne Kennedy, Marie Cavalier,

Is There a Role for Autologous Stem Cell Transplantation for Patients with Acute Myelogenous Leukemia? A Retrospective Analysis Nicolas Novitzky, Valda.

Favorable Overall Survival with Fully Myeloablative Allogeneic Stem Cell Transplantation for Follicular Lymphoma John Kuruvilla, Gregory Pond, Richard.

Incidence, Predisposing Factors, and Outcome of Engraftment Syndrome in Pediatric Allogeneic Stem Cell Transplant Recipients Irene Schmid, Daniel Stachel,

Incidence of Post-Transplant Bacterial Foodborne Pathogens in Hematopoietic Stem Cell Transplant Patients Nicole Boyle, Sara Podczervinski, Kim Jordan,

Efficacy of CD34+ Stem Cell Dose in Patients Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation after Total Body Irradiation Anurag K.

Sabina Kersting, Ronald J. Hené, Hein A. Koomans, Leo F. Verdonck

Shigeo Fuji, Hermann Einsele, Bipin N. Savani, Markus Kapp

Allogeneic Stem Cell Transplantation for Aplastic Anemia

Lung Function, Pulmonary Complications, and Mortality after Allogeneic Blood and Marrow Transplantation in Children Zühre Kaya, Daniel J. Weiner, Deniz.

Outcomes of Cord Blood Transplantation as Salvage Therapy after Graft Failure or Relapse after Prior Allogeneic Transplantation Rachel B. Salit, Filippo.

Predictive Limitations of Hematopoietic Stem Cell Transplantation Associated Mortality: A Machine Learning in-Silico Analysis of the EBMT - Acute Leukemia.

What is quality in a transplant program?

Chronic GVHD and Pretransplantation Abnormalities in Pulmonary Function Are the Main Determinants Predicting Worsening Pulmonary Function in Long-term.

Rituximab Administration within 6 Months of T Cell-Depleted Allogeneic SCT is Associated with Prolonged Life-Threatening Cytopenias Zachariah McIver,

Ultra-Low Dose IL-2 Expands Natural Regulatory T Cells and CD56bright NK Cells in Patients and Healthy Donors and Is Associated with Clinical Improvement.

Chimeric Antigen Receptor–Modified T Cells: Clinical Translation in Stem Cell Transplantation and Beyond Stanley R. Riddell, Michael C. Jensen, Carl.

Improved Outcome for Peripheral Blood Stem Cell Transplantation for Advanced Primary Myelodysplastic Syndrome Scott R. Solomon, Bipin N. Savani, Richard.

Allogeneic Hematopoietic Stem Cell Transplantation in FLT3-ITD–Positive Acute Myelogenous Leukemia: The Role for FLT3 Tyrosine Kinase Inhibitors Post-

Systemic Toxoplasmosis Post Allogeneic Stem Cell Transplantation (Allo-SCT): Lessons Learned from HIV? Marie von Lilienfeld-Toal, MD, Maria Gilleece,

Biology of Blood and Marrow Transplantation

Ribavirin in Desquamative Interstitial Pneumonia

Blood and Marrow Transplant Handbook

Evaluation of a Data-Derived Algorithm for Preemptive Use of Plerixafor for Stem Cell Harvest in Patients Eligible for Autologous Stem Cell Transplant.

Mammen Chandy Biology of Blood and Marrow Transplantation

Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives Brenda M. Sandmaier, Stephen Mackinnon, Richard.

Prediction and prevention of transplant-related mortality from pulmonary causes after total body irradiation and allogeneic stem cell transplantation

Treatment versus Transplant for Challenging Hematologic Disorders

Biology of Blood and Marrow Transplantation

Mary Eapen Biology of Blood and Marrow Transplantation

In Memoriam: E. Donnall Thomas

Presentation transcript:

Repair of Impaired Pulmonary Function Is Possible in Very-Long-Term Allogeneic Stem Cell Transplantation Survivors Natasha A. Jain, Priyanka A. Pophali, Jeffrey K. Klotz, Sawa Ito, Eleftheria Koklanaris, Kamna Chawla, Christopher S. Hourigan, Nicole Gormley, Bipin N. Savani, Austin John Barrett, Minoo Battiwalla Biology of Blood and Marrow Transplantation Volume 20, Issue 2, Pages 209-213 (February 2014) DOI: 10.1016/j.bbmt.2013.10.025 Copyright © 2014 Terms and Conditions

Figure 1 Proportions of patients with abnormal (<80% of the predicted) pretransplant PFTs. Proportions shown are not mutually exclusive. Biology of Blood and Marrow Transplantation 2014 20, 209-213DOI: (10.1016/j.bbmt.2013.10.025) Copyright © 2014 Terms and Conditions

Figure 2 Lung volumes at baseline and at 5, 10, and 15 years post-transplant. A, trend of forced expiratory volume in the first second (FEV1) at baseline, 5, 10 and 15 years post transplant. B, trend of vital capacity (VC) at baseline, 5, 10 and 15 years post transplant. C, trend of total lung capacity (TLC) at baseline, 5, 10 and 15 years post transplant. D, trend of FEV1/FVC ratio at baseline, 5, 10 and 15 years post transplant. Biology of Blood and Marrow Transplantation 2014 20, 209-213DOI: (10.1016/j.bbmt.2013.10.025) Copyright © 2014 Terms and Conditions

Figure 3 Mean DLCO adjusted for hemoglobin and alveolar ventilation at baseline and at 3, 5, 10, and 15 years. Biology of Blood and Marrow Transplantation 2014 20, 209-213DOI: (10.1016/j.bbmt.2013.10.025) Copyright © 2014 Terms and Conditions

Figure 4 (A) Kinetics of recovery of DLCO adjusted for hemoglobin and alveolar ventilation in the subjects who survived for 15 years post-transplant. (B) Kinetics of recovery of DLCO adjusted for hemoglobin and alveolar ventilation in the subjects who died beyond 3 years post-transplant. Biology of Blood and Marrow Transplantation 2014 20, 209-213DOI: (10.1016/j.bbmt.2013.10.025) Copyright © 2014 Terms and Conditions

Supplementary Figure 1 Unadjusted DLCO trend in a cohort of 138 patients after allo-SCT. Biology of Blood and Marrow Transplantation 2014 20, 209-213DOI: (10.1016/j.bbmt.2013.10.025) Copyright © 2014 Terms and Conditions